A National Institutes of Health public-private partnership aimed at accelerating Alzheimer’s disease drug development launched its “Big Data” portal on Wednesday, March 4, 2015, enabling researchers to share and analyze large biomedical datasets. The first wave of data was also released.
The venture brings together NIH, the U.S. Food and Drug Administration, and industry and academic scientists from a variety of disciplines with a goal of translate knowledge faster and more successfully into new therapies.
“This is an important initiative that could lead to novel targets for AD drug discovery,” says John Q. Trojanowski, MD, PhD, director of Penn’s Alzheimer’s Disease Core Center.
You can visit the The AMP AD Knowledge Portal here.